CaritasKlinikum St. Theresia, Saarbrücken, Germany.
Department of Epidemiology and Preventive Medicine, School of Public Health, Monash University, The Alfred Centre, Melbourne, Australia.
Eur J Cancer. 2016 Aug;63:11-24. doi: 10.1016/j.ejca.2016.04.010. Epub 2016 May 30.
Primary treatment of rectal cancer was the focus of the second St. Gallen European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Cancer Conference. In the context of the conference, a multidisciplinary international expert panel discussed and voted on controversial issues which could not be easily answered using published evidence. Main topics included optimal pretherapeutic imaging, indication and type of neoadjuvant treatment, and the treatment strategies in advanced tumours. Here we report the key recommendations and summarise the related evidence. The treatment strategy for localised rectal cancer varies from local excision in early tumours to neoadjuvant radiochemotherapy (RCT) in combination with extended surgery in locally advanced disease. Optimal pretherapeutic staging is a key to any treatment decision. The panel recommended magnetic resonance imaging (MRI) or MRI + endoscopic ultrasonography (EUS) as mandatory staging modalities, except for early T1 cancers with an option for local excision, where EUS in addition to MRI was considered to be most important because of its superior near-field resolution. Primary surgery with total mesorectal excision was recommended by most panellists for some early tumours with limited risk of recurrence (i.e. cT1-2 or cT3a N0 with clear mesorectal fascia on MRI and clearly above the levator muscles), whereas all other stages were considered for multimodal treatment. The consensus panel recommended long-course RCT over short-course radiotherapy for most clinical situations where neoadjuvant treatment is indicated, with the exception of T3a/b N0 tumours where short-course radiotherapy or even no neoadjuvant therapy were regarded to be an option. In patients with potentially resectable tumours and synchronous liver metastases, most panel members did not see an indication to start with classical fluoropyrimidine-based RCT but rather favoured preoperative short-course radiotherapy with systemic combination chemotherapy or alternatively a liver-first resection approach in resectable metastases, which both allow optimal systemic therapy for the metastatic disease. In general, proper patient selection and discussion in an experienced multidisciplinary team was considered as crucial component of care.
直肠癌的主要治疗方法是第二次圣加仑欧洲癌症研究与治疗组织(EORTC)胃肠癌会议的重点。在会议背景下,一个多学科的国际专家小组讨论并对一些有争议的问题进行了投票,这些问题无法仅通过已发表的证据来回答。主要议题包括最佳的治疗前影像学、新辅助治疗的适应证和类型,以及晚期肿瘤的治疗策略。在此,我们报告了关键建议,并总结了相关证据。局部直肠癌的治疗策略从早期肿瘤的局部切除到局部进展性疾病的新辅助放化疗(RCT)联合扩大手术而有所不同。最佳的治疗前分期是任何治疗决策的关键。专家组建议磁共振成像(MRI)或 MRI+内镜超声(EUS)作为强制性分期方式,除了 T1 早期肿瘤有局部切除的选择外,EUS 联合 MRI 被认为是最重要的,因为它具有更好的近场分辨率。大多数专家组成员建议对一些复发风险有限的早期肿瘤(即 MRI 显示筋膜清晰的 cT1-2 或 cT3aN0 或 MRI 显示位于提肛肌之上的 cT1-2 或 cT3aN0)进行单纯的直肠系膜全切除手术,而其他所有阶段均考虑进行多模式治疗。对于大多数需要新辅助治疗的临床情况,专家组建议进行长程 RCT 而非短程放疗,例外情况是 T3a/bN0 肿瘤,此时短程放疗甚至不进行新辅助治疗也被认为是一种选择。对于可能可切除的肿瘤和同步肝转移患者,大多数专家组成员不建议开始进行经典的氟嘧啶基 RCT,而是倾向于术前短程放疗联合全身联合化疗,或者在可切除转移灶中采用肝优先切除方法,这两种方法均可使转移性疾病获得最佳的全身治疗。总的来说,适当的患者选择和在经验丰富的多学科团队中的讨论被认为是治疗的关键组成部分。